Forte Biosciences (FBRX) Net Cash Flow Growth (5y) (2021 - 2026)
Powered by 
Analysis
Forte Biosciences (FBRX) Net Cash Flow Growth (5y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.72% |
| Mar 31, 2026 | -36.16% |
| Dec 31, 2025 | -19.40% |
| Sep 30, 2025 | -10.94% |
| Jun 30, 2025 | 40.77% |
| Mar 31, 2025 | 18.98% |
| Dec 31, 2024 | 58.25% |
| Sep 30, 2024 | -5.19% |
| Jun 30, 2024 | -18.29% |
| Mar 31, 2024 | 7.40% |
| Dec 31, 2023 | -20.33% |
| Sep 30, 2023 | 90.01% |
| Jun 30, 2023 | -22.92% |
| Mar 31, 2023 | 22.12% |
| Dec 31, 2022 | 40.31% |
| Sep 30, 2022 | 44.73% |
| Jun 30, 2022 | -15.12% |
| Mar 31, 2022 | -27.66% |
| Dec 31, 2021 | -31.81% |
| Sep 30, 2021 | -27.80% |